James D. Griffin | Academic Influence

James D. Griffin 's AcademicInfluence.com Rankings

James D. Griffin

Computer Science

#3245

World Rank

#3399

Historical Rank

#1270

USA Rank

Computational Linguistics

#136

World Rank

#139

Historical Rank

#15

USA Rank

Machine Learning

#335

World Rank

#339

Historical Rank

#61

USA Rank

Artificial Intelligence

#530

World Rank

#539

Historical Rank

#154

USA Rank

computer-science Degrees

Download Badge

Computer Science

James D. Griffin 's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is James D. Griffin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

James D. Griffin 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2005) (2933)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. (2003) (1709)
The roles of FLT3 in hematopoiesis and leukemia. (2002) (1478)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. (2005) (1471)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. (2006) (1286)
Granulocyte colony-stimulating factor and its receptor. (1991) (1076)
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications (2001) (696)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. (2005) (696)
Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. (1988) (675)
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. (1988) (640)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia (2007) (614)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. (2002) (613)
MAML1, a human homologue of Drosophila Mastermind, is a transcriptional co-activator for NOTCH receptors (2000) (605)
Expression of myeloid differentiation antigens on normal and malignant myeloid cells. (1981) (582)
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl (1996) (517)
JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region (1994) (507)
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. (2003) (449)
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. (2000) (431)
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. (1984) (426)
Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. (1991) (421)
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. (2003) (417)
t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway (2003) (417)
Growth Suppression of Pre-T Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling (2003) (401)
Critical role for Gab2 in transformation by BCR/ABL. (2002) (379)
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. (2005) (377)
Clonogenic cells in acute myeloblastic leukemia. (1986) (375)
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. (2007) (363)
The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells* (2000) (348)
Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. (1987) (326)
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia (2009) (321)
Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion (2009) (316)
Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. (1990) (312)
Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. (2000) (309)
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. (1994) (296)
Bcr/Abl activates transcription of the Bcl-X gene through STAT5. (2000) (292)
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity (2010) (291)
Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. (1991) (291)
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. (2002) (291)
Autocrine secretion of GM-CSF in acute myeloblastic leukemia. (1986) (290)
Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin (1991) (284)
ARG tyrosine kinase activity is inhibited by STI571. (2001) (281)
Molecular Cloning Of Human Paxillin, a Focal Adhesion Protein Phosphorylated by P210BCR/ABL(*) (1995) (278)
Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells (1985) (278)
Identification of a Family of Mastermind-Like Transcriptional Coactivators for Mammalian Notch Receptors (2002) (270)
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. (2011) (269)
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. (2004) (263)
Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. (1993) (259)
Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. (1990) (253)
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 (2000) (248)
The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. (1992) (248)
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. (2005) (248)
Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. (1985) (247)
BCR/ABL Regulates Expression of the Cyclin-dependent Kinase Inhibitor p27Kip1 through the Phosphatidylinositol 3-Kinase/AKT Pathway* (2000) (245)
Expression of the M-CSF (CSF-1) gene by human monocytes. (1987) (245)
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. (2005) (242)
The c-Mpl Ligand (Thrombopoietin) Stimulates Tyrosine Phosphorylation of Jak2, Shc, and c-Mpl (*) (1995) (241)
The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia (1987) (240)
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. (2017) (238)
Role of FLT3 in leukemia. (2002) (235)
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. (2003) (234)
Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. (1987) (233)
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. (2003) (226)
Induction of monocyte migration by recombinant macrophage colony-stimulating factor. (1988) (224)
Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. (1986) (220)
Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. (1988) (218)
Characterization of an antigen expressed by human natural killer cells. (1983) (217)
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. (2016) (213)
Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. (1992) (211)
AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia (2005) (210)
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. (2007) (203)
Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. (1987) (202)
Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. (1986) (200)
Differentiation patterns in the blastic phase of chronic myeloid leukemia. (1983) (196)
Heterogeneity of clonogenic cells in acute myeloblastic leukemia. (1985) (194)
Independent regulation of M-CSF and G-CSF gene expression in human monocytes. (1988) (193)
Prediction of Resistance to Small Molecule FLT3 Inhibitors (2004) (192)
t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway (2003) (184)
Surface marker anaylsis of acute myeloblastic leukemia: identifi- cation of differentiation-associated phenotypes. (1983) (184)
Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease (2002) (182)
cdc2 gene expression at the G1 to S transition in human T lymphocytes. (1990) (182)
Molecular mechanisms of transformation by the BCR-ABL oncogene. (2003) (182)
Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. (1987) (179)
B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. (1996) (176)
Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. (1982) (173)
Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies. (1986) (173)
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. (2004) (172)
Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. (1993) (171)
Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. (1983) (170)
Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. (2004) (170)
Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. (1989) (168)
CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. (1991) (168)
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. (1995) (168)
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. (2005) (167)
Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. (1987) (165)
Prognostic value of lymphocyte surface markers in acute myeloid leukemia. (1991) (151)
Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. (1989) (151)
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. (1994) (150)
The Related Adhesion Focal Tyrosine Kinase Forms a Complex with Paxillin in Hematopoietic Cells* (1996) (150)
Notch receptors and hematopoiesis. (2001) (148)
Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes. (1987) (146)
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. (1992) (146)
The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis. (2006) (146)
Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. (1996) (144)
Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo. (1988) (143)
CRKL Links p210BCR/ABL with Paxillin in Chronic Myelogenous Leukemia Cells (*) (1995) (142)
Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level. (1989) (137)
Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. (1990) (137)
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. (2005) (137)
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. (2008) (136)
Regulation of the production and function of granulocytes and monocytes. (1988) (134)
Acute myeloid leukemia and acute promyelocytic leukemia. (2003) (131)
FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins (2004) (131)
p130CAS Forms a Signaling Complex with the Adapter Protein CRKL in Hematopoietic Cells Transformed by the BCR/ABL Oncogene* (1996) (131)
Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. (1988) (128)
Transforming activity of MECT1‐MAML2 fusion oncoprotein is mediated by constitutive CREB activation (2005) (127)
T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia (1983) (127)
Role of B7-1 in mediating an immune response to myeloid leukemia cells. (1995) (127)
CD2 is involved in maintenance and reversal of human alloantigen- specific clonal anergy (1994) (126)
Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia. (1988) (125)
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. (2002) (125)
The Role of Protein Composition in Specifying Nuclear Inclusion Formation in Polyglutamine Disease* (2001) (123)
Steel Factor Induces Tyrosine Phosphorylation of CRKL and Binding of CRKL to a Complex Containing c-Kit, Phosphatidylinositol 3-Kinase, and p120CBL* (1997) (122)
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. (2005) (120)
Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor (2013) (119)
Differential expression of CD11b/CD18 (Mo1) and myeloperoxidase genes during myeloid differentiation. (1989) (119)
BCR/ABL Directly Inhibits Expression of SHIP, an SH2-Containing Polyinositol-5-Phosphatase Involved in the Regulation of Hematopoiesis (1999) (119)
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. (2009) (118)
The Adapter Protein Crkl Links Cbl to C3G after Integrin Ligation and Enhances Cell Migration* (1999) (116)
Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition* (2006) (112)
Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. (1991) (112)
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. (1996) (110)
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases (2010) (109)
NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. (2004) (107)
Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells. (1990) (105)
Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. (1992) (104)
Inhibition of mutant FLT 3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC 412 (2002) (104)
Expression of MY7 antigen on myeloid precursor cells. (1983) (104)
Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA) (1983) (102)
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. (2007) (101)
Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. (1981) (101)
Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms (2011) (101)
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. (2006) (100)
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. (2007) (99)
Treatment of myeloid leukemic cells with the phosphatase inhibitor okadaic acid induces cell cycle arrest at either G1/S or G2/M depending on dose (1992) (99)
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies (2005) (98)
Involvement of p130Cas and p105HEF1, a Novel Cas-like Docking Protein, in a Cytoskeleton-dependent Signaling Pathway Initiated by Ligation of Integrin or Antigen Receptor on Human B Cells* (1997) (98)
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. (1993) (96)
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. (2004) (96)
Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce rapid phosphorylation and activation of the proto-oncogene Raf-1 in a human factor-dependent myeloid cell line. (1991) (95)
Differential Signaling after β1 Integrin Ligation Is Mediated Through Binding of CRKL to p120 CBL and p110 HEF1 * (1997) (95)
Surface marker analysis of acute myeloblastic leukemia: identification of differentiation-associated phenotypes. (1983) (95)
Structure of the gene encoding the human leukocyte adhesion molecule-1 (TQ1, Leu-8) of lymphocytes and neutrophils. (1990) (95)
Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. (1992) (95)
Relationship of oligomerization to enzymatic and DNA-binding properties of the SV40 large T antigen (1982) (94)
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. (2004) (94)
The biology of GM-CSF: regulation of production and interaction with its receptor. (1990) (94)
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. (2010) (94)
Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. (1992) (94)
Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. (1994) (91)
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. (2012) (91)
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility (1999) (90)
The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors (1997) (90)
Induction of proliferation of purified human myeloid progenitor cells: a rapid assay for granulocyte colony-stimulating factors. (1984) (90)
Repurposing of Kinase Inhibitors for Treatment of COVID-19 (2020) (89)
The Notch Regulator MAML1 Interacts with p53 and Functions as a Coactivator* (2007) (89)
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial (2021) (89)
Resistance to imatinib (Glivec): update on clinical mechanisms. (2003) (89)
Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. (2004) (89)
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. (2008) (89)
NOTCH1-induced T-cell leukemia in transgenic zebrafish (2007) (88)
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells (2007) (87)
Characterization of Two SHP-2-associated Binding Proteins and Potential Substrates in Hematopoietic Cells* (1997) (87)
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model (2005) (85)
Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. (1997) (83)
Structure of a pseudokinase domain switch that controls oncogenic activation of Jak kinases (2013) (83)
A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets (2013) (81)
The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. (1996) (80)
Inhibition of USP10 induces degradation of oncogenic FLT3. (2017) (80)
MAML 1 , a human homologue of Drosophila Mastermind , is a transcriptional coactivator for NOTCH receptors (2000) (80)
A Robust Error Model for iTRAQ Quantification Reveals Divergent Signaling between Oncogenic FLT3 Mutants in Acute Myeloid Leukemia* (2009) (80)
In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level. (1987) (80)
Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. (1983) (79)
Differentiation of myeloid cells is accompanied by increased levels of pp60c-src protein and kinase activity. (1986) (79)
Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. (1994) (78)
SHIP1, an SH2 Domain Containing Polyinositol-5-phosphatase, Regulates Migration through Two Critical Tyrosine Residues and Forms a Novel Signaling Complex with DOK1 and CRKL* (2001) (75)
Mechanisms of Transformation by the BCR/ABL Oncogene (2001) (74)
Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. (1981) (73)
Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product (1991) (73)
Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. (1985) (72)
Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I. (1992) (72)
Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. (1991) (72)
Protein kinase activity associated with simian virus 40 T antigen. (1979) (72)
The biology of signal transduction inhibition: basic science to novel therapies. (2001) (71)
Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. (1990) (71)
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines (2000) (70)
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. (2005) (70)
In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells. (1988) (70)
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells (2008) (70)
Aberrantly activated AREG–EGFR signaling is required for the growth and survival of CRTC1–MAML2 fusion-positive mucoepidermoid carcinoma cells (2014) (69)
Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. (2004) (68)
Use of surface markers to identify a subset of acute myelomonocytic leukemia cells with progenitor cell properties. (1983) (67)
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia (2010) (67)
Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells. (1990) (66)
T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro. (1986) (64)
Cloning and expression of a gamma-interferon-inducible gene in monocytes: a new member of a cytokine gene family. (1989) (64)
Isolation of myeloid progenitor cells from peripheral blood of chronic (1982) (64)
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth‐inhibitory and VEGF‐suppressive effects of rapamycin in leukemic cells (2005) (63)
Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. (1984) (62)
Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma (2014) (62)
Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. (1989) (62)
Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. (1985) (62)
The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia , but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia (2005) (62)
Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. (1991) (61)
An enzyme-linked immunosorbent assay (ELISA) for the detection of monoclonal antibodies to cell surface antigens on viable cells. (1982) (61)
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. (2010) (61)
Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. (1986) (61)
Transforming growth factor-beta inhibits phosphorylation of the retinoblastoma susceptibility gene product in human monocytic leukemia cell line JOSK-I. (1992) (61)
Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line. (1991) (60)
The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development. (2007) (60)
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. (2009) (60)
Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. (1991) (60)
Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. (2001) (58)
A Fragment of Paxillin Binds the α4Integrin Cytoplasmic Domain (Tail) and Selectively Inhibits α4-Mediated Cell Migration* (2002) (58)
Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750. (1995) (56)
Signaling Functions of the Tyrosine Residues in the βc Chain of the Granulocyte-Macrophage Colony-Stimulating Factor Receptor (1997) (54)
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. (2016) (53)
Interaction of the receptor tyrosine kinase p145c‐kit with the p210bcr/abl kinase in myeloid cells (1996) (52)
Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism* (2010) (50)
Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells (2011) (50)
The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. (1990) (50)
Expression of Myeloid Differentiation Antigens in Acute Myeloblastic Leukemia (1984) (49)
Interferon‐γ induces expression of the interleukin 2 receptor gene in human monocytes (1987) (49)
rel Is rapidly tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils. (1994) (49)
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097 (2015) (49)
Granulocyte‐Macrophage colony‐stimulating factor and steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor‐dependent hematopoietic cell line (1992) (47)
The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. (1987) (47)
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism (2020) (47)
Leukemia stem cells and constitutive activation of NF-kappaB. (2001) (47)
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies (2014) (47)
Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. (1989) (46)
Inhibition of p21ras activation blocks proliferation but not differentiation of interleukin-3-dependent myeloid cells. (1994) (46)
Morphologic characteristics of erythroleukemia (Acute Myeloid Leukemia; FAB‐M6): A CALGB study (1995) (45)
The human granulocyte‐macrophage colony‐stimulating factor receptor is capable of initiating signal transduction in NIH3T3 cells. (1993) (45)
T cell regulation of myelopoiesis: analysis at a clonal level. (1984) (44)
Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. (1991) (44)
Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells. (1995) (43)
A low affinity chimeric human alpha/beta-granulocyte-macrophage colony-stimulating factor receptor induces ligand-dependent proliferation in a murine cell line. (1994) (43)
Tissue factor gene expression in acute myeloblastic leukemia. (1989) (43)
Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells (2013) (42)
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. (2004) (42)
Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte‐macrophage colony‐stimulating factor (1989) (42)
The biology of acute myeloblastic leukemia. (1987) (42)
Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells. (1989) (42)
Idiopathic thrombocytopenia in association with extragonadal germ cell cancer. (1983) (41)
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. (2008) (41)
The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. (1995) (41)
Generation of Monoclonal Antibodies to a Human Natural Killer Clone (41)
Conservation of myeloid surface antigens on primate granulocytes. (1983) (40)
Effects of interferon-gamma on proto-oncogene expression during induction of human monocytic differentiation. (1987) (39)
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. (2014) (39)
T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. (1983) (39)
Establishment of an interleukin 2-dependent T cell line derived from a patient with severe aplastic anemia, which inhibits in vitro hematopoiesis. (1986) (39)
Discovery of a selective irreversible BMX inhibitor for prostate cancer. (2013) (38)
Clinical pharmacology of low-dose cytosine arabinoside (1985) (38)
Involvement of the adapter protein CRKL in integrin-mediated adhesion (1999) (38)
A blast subclone of the HL-60 human promyelocytic cell line. (1981) (38)
The Mastermind-like 1 (MAML1) Co-activator Regulates Constitutive NF-κB Signaling and Cell Survival* (2010) (38)
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity (2011) (37)
Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo (1997) (37)
Point mutations in the FLT3 gene in AML. (2001) (36)
Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. (1997) (36)
Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia (2016) (36)
Hematologic remission and cytogenetic improvement after treatment of stable‐phase chronic myelogenous leukemia with continuous infusion of low‐dose cytarabine (1993) (35)
Development of a histiocytic medullary reticulosis-like syndrome during the course of acute lymphocytic leukemia. (1978) (35)
Measurements of the molecular size of the simian virus 40 large T antigen (1978) (35)
p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. (1994) (35)
Differential expression of HLA-DR antigens in subsets of human CFU-GM. (1985) (34)
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML (2016) (34)
A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. (2002) (34)
Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. (2010) (33)
Redirection to the bone marrow improves T cell persistence and antitumor functions (2018) (33)
Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. (2005) (33)
Signaling Domains of the βc Chain of the GM‐CSF/IL‐3/IL‐5 Receptor (1999) (33)
Characterization of myeloid leukemias with monoclonal antibodies 3C5 and MY9 (1985) (33)
The effects of phorbol myristate acetate and chemotactic peptide on transmembrane potentials and cytosolic free calcium in mature granulocytes evolve sequentially as the cells differentiate. (1987) (32)
Phenotypic complementation of the SV40 tsA mutant defect in viral DNA synthesis following microinjection of SV40 T antigen (1978) (32)
Tyrosine phosphorylation of Shc is not required for proliferation or viability signaling by granulocyte-macrophage colony-stimulating factor in hematopoietic cell lines. (1996) (32)
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation. (1997) (31)
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting (2012) (31)
A pericentric inversion of chromosome 16 is associated with dysplastic marrow eosinophils in acute myelomonocytic leukemia. (1984) (31)
Surface Marker Analysis of Acute Myeloblastic Leukemia (1985) (30)
Internalization of the granulocyte-macrophage colony-stimulating factor receptor is not required for induction of protein tyrosine phosphorylation in human myeloid cells. (1991) (30)
Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells (2002) (30)
Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells (2015) (30)
Involvement of spermidine in proliferation and differentiation of human promyelocytic leukemia cells. (1984) (29)
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. (2003) (29)
Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail? (1990) (28)
Interferon-gamma increases the expression of the gene encoding the beta subunit of the granulocyte-macrophage colony-stimulating factor receptor. (1992) (28)
Microgranular acute promyelocytic leukemia diagnosed by flow cytometry. (1983) (28)
Cellular and clinical pharmacology of low-dose ara-C. (1985) (27)
Aminopeptidase Inhibitors Inhibit Proliferation and Induce Apoptosis of K562 and STI571-resistant K562 Cell Lines Through the MAPK and GSK-3ß Pathways (2003) (27)
Hemopoietins in oncology: factoring out myelosuppression. (1989) (26)
Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. (1992) (26)
Lymphocytic thymoma associated with T-cell lymphocytosis. (1978) (25)
A naturally occurring bone marrow-chimeric primate. II. Environment dictates restriction on cytolytic T lymphocyte-target cell interactions (1985) (25)
Polyamine requirements for induction of HL-60 promyelocyte differentiation by leukocyte-conditioned medium and phorbol ester. (1984) (25)
An elevation in the concentration of free cytosolic calcium is sufficient to activate the oxidative burst of granulocytes primed with recombinant human granulocyte-macrophage colony-stimulating factor. (1989) (25)
Biology of acute myeloid leukaemia. (1986) (24)
Effects of 1-beta-D-arabinofuranosylcytosine and phorbol ester on differentiation of human K562 erythroleukemia cells. (1985) (24)
Acute undifferentiated leukemia: induction of partial differentiation by phorbol ester. (1985) (24)
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies (2019) (24)
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. (2015) (24)
Monocytes enhance gamma-interferon-induced inhibition of myeloid progenitor cell growth through secretion of tumor necrosis factor. (1988) (23)
The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma (2021) (23)
Effect of ara-A on differentiation and proliferation of HL-60 cells. (1984) (23)
The use of monoclonal antibodies in the characterization of myeloid leukemias. (1987) (23)
NOTCH1-Induced T-Cell Leukemia in Transgenic Zebrafish. (2006) (23)
Colony-stimulating factor gene expression in human acute myeloblastic leukemia cells is posttranscriptionally regulated. (1989) (23)
Generation time of leukaemic blast progenitor cells. (1983) (22)
Effects of recombinant human granulocyte-macrophage colony-stimulating factor on intracellular pH in mature granulocytes. (1988) (22)
Enforced CDK4 expression in a hematopoietic cell line confers resistance to the G1 arrest induced by ionizing radiation (1998) (22)
Isolation of myeloid progenitor cells from peripheral blood of chronic myelogenous leukemia patients. (1982) (22)
Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies. (1991) (21)
Structure-guided development of covalent TAK1 inhibitors. (2017) (21)
Preexposure of resting B cells to interferon-gamma enhances their proliferative response to subsequent activation signals. (1987) (21)
Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. (2015) (21)
Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression. (1994) (21)
A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. (2006) (21)
Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support. (1992) (21)
Identification of functionally distinct domains of human granulocyte- macrophage colony-stimulating factor using monoclonal antibodies (1991) (21)
Identification and initial characterization of a new low-molecular-weight virus-encoded T antigen in a line of simian virus 40-transformed cells (1980) (21)
Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice. (1999) (20)
Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung. (1985) (19)
Clinical pharmacology of low-dose cytosine arabinoside. (1985) (19)
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML (2016) (19)
Isolation and characterization of human B lymphocyte enriched populations. I. Purification of B cells by immune rosette depletion. (1983) (19)
Relationship between HLA-DR expression by normal myeloid progenitor cells and inhibition of colony growth by prostaglandin E. Implications for prostaglandin E resistance in chronic myeloid leukemia. (1986) (18)
Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development (2001) (18)
Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors (2010) (18)
Leukemic colony-forming cells in acute myeloblastic leukemia: maturation hierarchy and growth conditions. (1987) (18)
Resistance to targeted therapy in leukaemia (2002) (18)
Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene. (2004) (18)
Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. (1999) (17)
Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R (2014) (16)
Following the cytokine signaling pathway to leukemogenesis: a chronology. (2008) (16)
Management of chronic myelogenous leukemia. (1986) (16)
Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. (2016) (16)
Clonogenic cells in acute myeloblastic leukaemia. (2009) (16)
Enzymatic activities associated with the SV40 large T antigen. (1980) (16)
Clinical applications of colony-stimulating factors. (1988) (16)
Inhibition of the deubiquitinase USP10 induces degradation of SYK (2020) (16)
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. (2017) (15)
TPA induces differentiation of purified human myeloblasts in the absence of proliferation. (1985) (15)
Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high‐dose cytosine arabinoside and melphalan (1994) (15)
Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages. (1989) (14)
Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies (2016) (14)
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. (2017) (14)
Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target? (2013) (14)
Corrigendum: Tyrosine phosphorylation of p95(Vav) in myeloid cells is regulated by GM-CSF, IL-3 and Steel factor and is constitutively increased by p210(BCR/ABL) (The EMBO Journal (1995) 14 (257-265)) (1996) (14)
Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony- forming cells (1985) (14)
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition (2017) (14)
SB1518: A Potent and Orally Active JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders. (2007) (13)
Effects of recombinant human granulocyte‐macrophage colony‐stimulating factor (GM‐CSFrh) on transmembrane electrical potentials in granulocytes: Relationship between enhancement of ligand‐mediated depolarization and augmentation of superoxide anion (O −2 ) production (1989) (13)
Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML (2016) (13)
Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia (2020) (13)
Demonstration of interleukin-1 beta transcripts in acute myeloblastic leukemic cells by in situ hybridization. (1990) (13)
The role of colony stimulating factors in leukaemogenesis. (1986) (12)
Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming (2017) (12)
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis (2013) (12)
Effect of phorbol ester on differentiation of human myeloid colony forming cells (CFU-C). (1983) (12)
BLOOD: Editor's Report 1994 (1994) (12)
Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. (2017) (12)
Selective cytotoxicity of the SM1 monoclonal antibody towards small cell carcinoma of the lung. (1985) (12)
Chronic granulocytic leukemia: the heterogeneity of stem cell differentiation within a single disease entity. (1985) (12)
Hemopoietins and leukemia. (1989) (12)
FLT3 tyrosine kinase as a target in acute leukemias. (2004) (12)
The small molecule tyrosine kinase inhibitor AMN 107 inhibits TEL-PDGFR and FIP 1 L 1-PDGFR in vitro and in vivo (2005) (12)
Interaction maps for kinase inhibitors (2005) (12)
Development of 'DFG-out' inhibitors of gatekeeper mutant kinases. (2012) (11)
Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside". (2017) (11)
The Pursuit of Archeology in the United States (1959) (11)
Signaling functions of the tyrosine residues in the betac chain of the granulocyte-macrophage colony-stimulating factor receptor. (1997) (11)
Signal transduction of steel factor and granulocyte-macrophage colony-stimulating factor: differential regulation of transcription factor and G1 cyclin gene expression, and of proliferation in the human factor-dependent cell line MO7. (1994) (11)
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase (2017) (11)
An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit. (2012) (11)
Role of B 7-1 in Mediating an Immune Response to Myeloid Leukemia Cells (2002) (11)
The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation. (2000) (11)
Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside. (1987) (11)
Advances in Brief Prediction of Resistance to Small Molecule FLT 3 Inhibitors : Implications for Molecularly Targeted Therapy of Acute Leukemia (2004) (10)
Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy (2017) (10)
Treatment of the Elastic Phase of Chronic Myelogenous Leukemia with High‐Dose Cytosine Arabinoside (1988) (9)
Acquisition of formyl peptide receptors during normal human myeloid differentiation (1987) (9)
Treatment patterns and healthcare resource utilization in patients with FLT3‐mutated and wild‐type acute myeloid leukemia: A medical chart study (2019) (9)
Phase II Evaluation of N-Trifluoroacetyladriamycin-14-Valerate (AD 32) (1982) (9)
Targeted Therapy with Imatinib: An Exception or a Rule? (2005) (9)
Epidermal Growth Factor – Independent Transformation of Ba / F 3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression (2005) (9)
Enrichment of myeloid progenitor cells from normal human bone marrow using an immune-rosette technique. (1985) (9)
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM) (2020) (9)
JAK2 gets histone H3 rolling. (2009) (9)
Simultaneous Administration of AMN107 and Imatinib in the Treatment of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia. (2005) (8)
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia (2019) (8)
A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo. (1997) (8)
Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent Manner. (2010) (8)
The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors (2004) (8)
Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs. (2009) (8)
LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo. (2002) (8)
Surface immunoglobulin-mediated signal transduction involves rapid phosphorylation and activation of the protooncogene product Raf-1 in human B-cells. (1992) (7)
Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies (2014) (7)
Immunological and cytogenetic studies in two cases of B-cell acute lymphoblastic leukemia (Burkitt's type). (1983) (7)
Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances (2016) (6)
Blood's 70th anniversary: arsenic--from poison pill to magic bullet. (2016) (6)
Cell-Surface Antigens in Acute Leukemia (1982) (6)
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2 (2021) (6)
Current Therapies Under Investigation for COVID-19. (2020) (6)
Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID‐19 therapy (2022) (6)
Mb1, a plasma membrane antigen selectively expressed by U-937 cells. (1985) (6)
The C-Terminus of c-Abl Is Required for Proliferation and Viability Signaling in a c-Abl/Erythropoietin Receptor Fusion Protein (1998) (5)
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma (2022) (5)
Human Bone Marrow Depleted of CD 33-Positive Cells Mediates Delayed but Durable Reconstitution of Hematopoiesis : Clinical Trial of MY 9 Monoclonal Antibody-Purged Autografts for the Treatment of Acute Myeloid Leukemia (2003) (5)
Low dose ara-C administered by continuous subcutaneous infusion: a pharmacologic evaluation. (1986) (5)
Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes (2021) (5)
PCN48 NON-ADHERENCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IS ASSOCIATED WITH SHORT- AND LONG-TERM NEGATIVE IMPACTS ON HEALTH CARE RESOURCE UTILIZATION AND COSTS (2010) (5)
Signal transduction and cellular functions of the TEL/ARG oncoprotein (2005) (5)
Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML (2004) (5)
Southern blot analysis of BII cell line--a putative variant of HL-60. (1987) (5)
The Transcriptional Coactivator Maml 1 is Required for Notch 2-mediated Marginal Zone B cell Development (2007) (5)
Acquisition of formyl peptide receptors during normal human myeloid differentiation. (1987) (4)
Monocyte interleukin-1 secretion is regulated by the sequential action of gamma-interferon and interleukin-2 involving monocyte surface expression of interleukin-2 receptors. (1989) (4)
The Pregnant Muse: Language and Birth in "A Song of the Rolling Earth" (1983) (4)
Comparison of Adherence Between Nilotinib and Dasatinib as Second-Line Therapies In Chronic Myeloid Leukemia. (2010) (4)
Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia (2008) (4)
A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML) (2012) (4)
The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK 787 / ZK 222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment 1 (1998) (4)
The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein. (1998) (4)
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM) (2021) (4)
O-306 Novel somatic mutations in the juxtamembrane domain of c-Met in small cell lung cancer: implications in cytoskeletal functions and cell motility (2003) (3)
Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance. (2004) (3)
CML cell trafficking: Influence of the stromal microenvironment (2012) (3)
Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors. (2018) (3)
FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML) (2016) (3)
In vivo activity of AMN107, as selective Bcr-Abl kinase inhibitor, in murine leukemia models (2005) (3)
Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes. (1987) (3)
mesothelial cells and human malignant mesothelioma cells lines in vitro Expression of colony-stimulating factor genes by normal human (2011) (3)
3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance (2021) (3)
Amsacrine in refractory acute leukemia. (1985) (3)
AMN107: Inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase (2005) (3)
AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models. (2004) (3)
Differentiation-Associated Stages of Clonogenic Cells in Acute Myeloblastic Leukemia Identified by Monoclonal Antibodies (1986) (3)
PCN47 COMPARISON OF HEALTH CARE RESOURCE UTILIZATION AND COSTS BETWEEN NILOTINIB AND DASATINIB AS SECOND LINE THERAPIES IN CHRONIC MYELOID LEUKEMIA (CML) (2010) (2)
Growth factors required for proliferation of clonogenic cells in acute myeloblastic leukemia (AML). (1987) (2)
Identification of Novel Splice Variants of Multiple Genes Using Genome-Wide Analysis of Alternative Splicing in Patients with Acute Myeloid Leukemia. (2009) (2)
Molecular pharmacology of cytosine arabinoside (1985) (2)
Small Molecule Activators Of AMPK Block The Glycogen Production Required For Transformation Of Myeloid Leukemia Cells (2013) (2)
BCR/ABL Induces Expression of Vascular Endothelial Growth Factor and its Transcriptional Activator, Hypoxia Inducible Factor-1α, through a Pathway Involving PI3-Kinase and the Mammalian Target of Rapamycin (mTOR) (2002) (2)
Kinase Domain Mutations in JAK2V617F Confer Resistance to the Novel JAK2 Inhibitor Ruxolitinib (2011) (2)
The cytokine-activated tyrosine kinase JAK 2 activates Raf-1 in a p 21 ras-dependent manner ( signal transduction / baculovirus / mammalian cells / oncogenes ) (2005) (2)
Expression of an antigen defined by a monoclonal antibody (SA-1) on normal and malignant cells. (2009) (2)
Treatment patterns of chronic myelogenous leukemia patients with suboptimal responses to imatinib. (2016) (2)
myelogenous leukemia cells resistant to kinase inhibitors The STAT5 inhibitor pimozide decreases survival of chronic (2011) (2)
Editor's Report 1996 (1996) (2)
Caught in the slips (2010) (2)
Pharmacological profile of the FLT3-Tyrosine Kinase Inhibitor AST487 (2005) (1)
CRKL Links p210 with Paxillin in Chronic Myelogenous Leukemia Cells* (1995) (1)
Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Indetifies Potential Novel Targets (2011) (1)
Effects of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSFrh) on transmembrane electrical potentials in granulocytes: relationship between enhancement of ligand-mediated depolarization and augmentation of superoxide anion (O2-) production. (1989) (1)
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia (2020) (1)
Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia (2006) (1)
The Case of Many Persons (1988) (1)
Inhibitors of Protein Kinases and Protein Phosphates Contributors (2005) (1)
Patient and Physician Preferences for Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients Not Candidates for Intensive Chemotherapy (2021) (1)
PKC412 Effectively Inhibits Constitutively Activated FGFR3 Mutants in Murine Leukemia Models and t(4;14) Myeloma Cell Lines. (2004) (1)
Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony-forming cells. (1985) (1)
Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia (2016) (1)
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations (2020) (1)
respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Patients with acute myeloid leukemia and an activating mutation in FLT3 (2013) (1)
Regulation of colony-stimulating factor production by normal and leukemic human cells (1989) (1)
Identification and purification of human erythroid progenitor cells by monoclonal antibody to the transferrin receptor (TÜ 67) (1988) (1)
Identification of Potential Therapeutic Targets Using Genome-Wide Analysis of Alternative Splicing (AS) In Patients with Acute Myeloid Leukemia (AML) (2010) (1)
Comparison of Healthcare Utilization and Costs Between Nilotinib and Dasatinib as Second Line Therapies in Chronic Myeloid Leukemia. (2009) (1)
Cameron's search for a cure. (1991) (1)
Protein kinase activity associated with simian virus 40 T antigen ( immunoprecipitation assay / casein phosphorylation / tsA mutant protein ) (1)
Treatment Patterns and Healthcare Resource Utilization in Patients with Relapsed/Refractory Acute Myeloid Leukemia and a Subset with IDH1-Mutation: A United States Medical Chart Review Study (2018) (1)
Cellular interaction regulating the production of colony-stimulating factors. (1990) (1)
Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy. (2012) (0)
on chronic myelogenous leukemia cells in vitro Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) (2013) (0)
Abstract B01: Improve MEK/ERK targeting in mutant KRAS lung cancer (2014) (0)
Depend on Increased Metabolism Activate Growth and Survival Pathways Human Acute Myeloid Leukemia That in CBL Novel Oncogenic Mutations of Signal Transduction (2010) (0)
Transformation of Myeloid Cells by the BCR/ABL Oncogene (1998) (0)
Notch receptor signal transduction (2000) (0)
Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML) (2018) (0)
Review EssayINote critique Cameron's Search for a Cure* (1991) (0)
2002 -- 2003 FACULTY COMMITTEES FACULTY CHAIR - W. CARSON FACULTY CHAIR ELECT - C. JENNINGS (2003) (0)
Medical assistance for the sick poor in ante-bellum Savannah. (1969) (0)
The Case of One Person (1988) (0)
Asylum at lower Fort Garry, 1874-1886. (1980) (0)
Abstract 3026: Targeting aberrantly activated AREG-EGFR signaling in CRTC1-MAML2-positive mucoepidermoid carcinoma. (2013) (0)
Georgia and the United States Constitution 1787-1789. (1977) (0)
The Honorable Mary Macdonald: a lesson in attitude. (1981) (0)
An unusual case of unequal chest expansion (2010) (0)
Hyperphoria of large magnitude--a case report. (1972) (0)
Anesthesiology Keywords Review (2010) (0)
Identification of Common Target Genes of the BCR/ABL and FLT3-ITD Tyrosine Kinases by Microarray Analysis. (2004) (0)
Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies (2014) (0)
Stromal-Derived Factor-1? The BCR/ABL Oncogene Alters the Chemotactic Response to (2012) (0)
BCR/ABL and Signal Transduction Pathways (1997) (0)
Essential Role for the MAML1 Co-Activator In T-ALL (2010) (0)
A New Model to Evaluate Signaling of Raf in Hematopoietic Cells. (2004) (0)
Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study Identification of BCR-ABL point mutations conferring resistance to the (2013) (0)
positive chronic eosinophilic leukemia - The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA (2013) (0)
The Jak2 V617F Oncogene Associated with Polycythemia Vera Requires a Functional FERM Domain for Transformation and for Expression of the Myc and Pim Proto-Oncogenes. (2006) (0)
cells STAT5 activation contributes to growth and viability in Bcr/Abl-transformed (2013) (0)
Jak2 in peripheral-blood samples A sensitive high-throughput method to detect activating mutations of (2011) (0)
Monocyte dependent and independent in vitro regulation of granulocyte macrophage colony forming units by subpopulations of peripheral blood t cells (1985) (0)
Using a zebrafish Danio rerio model system to study NOTCH1-induced T-cell leukaemia (2008) (0)
The JAK2V617F Oncogene, Associated with Myeloproliferative Neoplasms, Requires Expression of Inducible Phosphofructokinase/Fructose Bisphosphatase 3 for Cell Growth and Increased Metabolic Activity (2010) (0)
Abstract PR04: Degradation of leukemia oncogenes: A novel approach to therapy of leukemia (2017) (0)
Abstract 6248: Inhibiting β-catenin in AML by targeting DDX5 (2023) (0)
leukemia: direct analysis using partially purified colony- forming cells Expression of Ia antigens on myeloid progenitor cells in chronic myeloid (2011) (0)
Inhibition of the NPM-ALK Fusion Tyrosine Kinase in Hematopoietic Neoplasia by the Small Molecule Tyrosine Kinase Antagonist TAE684. (2006) (0)
FOXO Transcription Factors Are Negatively Regulated by p38 Map Kinases Downstream of FLT3 Receptor Signaling. (2005) (0)
Hybridoma cell line (1996) (0)
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2 (2022) (0)
PKC412 Inhibits the ZNF198-FGFR1 Fusion Tyrosine Kinase and Is Efficacious in Treatment of t(8;13)(p11;q12) Associated Stem Cell Myeloproliferative Disease. (2004) (0)
BCR-ABL Transformation Requires Glycogen Synthase 1 (GYS1) Expression for Cell Growth and Increased Glycogen Production (2012) (0)
Surface Antigens in a Patient With Blast Crisis of Chronic Myeloid Leukemia (2005) (0)
Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mut and FLT3-Wt Acute Myeloid Leukemia: A Multi-Country Medical Chart Study (2017) (0)
Estaurospina derivatives as inhibitors of tyrosine kinase activity flt3 receptor. (2002) (0)
UseofSM-1Monoclonal Antibody andHumanComplementinSelective Killing ofSmallCellCarcinomaoftheLung (1985) (0)
Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells (2015) (0)
The MAML1 Transcriptional Co-Activator Is Required for the Development of Marginal Zone B Cells. (2006) (0)
Selective Cytotoxicity of the SM 1 Monoclonal Antibody towards Small Cell Carcinoma of the Lung 1 (2006) (0)
dependent mechanism stimulate monocyte cytotoxicity through a tumor necrosis factor- Human granulocyte-monocyte colony-stimulating factor and interleukin 3 (2011) (0)
Causative Factors Involved in Development of Resistance to Tyrosine Kinase Inhibition and Novel Strategies Designed to Override This Resistance (2011) (0)
LARGE SV 40 T ANTIGEN MOLECULAR WEIGHT 219 problematic if the genuine size of the large (0)
Characteristics of Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy (2012) (0)
Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors. (2012) (0)
BCR-ABL Induces Error-Prone Single Strand Annealing in Transformed Cells. (2007) (0)
The Jak2V617F Oncogene Associated with Polycythemia Vera Regulates G1/S-Phase Transition. (2005) (0)
Granulocyte-Macrophage Colony-Stimulating Factor Receptor c Chain of the β Signaling Functions of the Tyrosine Residues in the (2013) (0)
Maintenance Therapy in Patients with FLT3-ITD-Mutation-Positive Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: Real-World Survival (2021) (0)
Activation of beta-catenin by mutant FLT3 receptors is mediated by GSK3-beta (2007) (0)
at a clonal level In vitro regulation of human hematopoiesis by natural killer cells: analysis (2011) (0)
of the Myc and Pim proto-oncogenes requires a functional FERM domain for transformation and for expression The Jak2V617F oncogene associated with myeloproliferative diseases (2013) (0)
Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3-Mutated (FLT3mut) and FLT3-Wild Type (FLT3wt) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study (2018) (0)
Scietific program and abstractThe application of monoclonal antibodies for the detection and classification of AML (1986) (0)
Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib As Second-Line Therapy (2012) (0)
IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels (2014) (0)
Studies of TAK 1-centered polypharmacology with novel covalent TAK 1 inhibitors (2017) (0)
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism (2020) (0)
acute lymphoblastic The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic (2005) (0)
Over-expression of CXCR4 targets donor T-cells to tumour niches and enhances graft-versus-lymphoma (2013) (0)
Aberrant Splicing In Patients With AML Is Associated With Over- Expression Of Specific Splicing Factors (2013) (0)
Potentiation of the Effects of Nilotinib by Combination with Plerixafor in a Mouse Model of BCR-ABL-Positive Residual Disease (2011) (0)
Nilotinib appears beneficial in Phase I study for patients with Gleevec-resistant CML (2006) (0)
Abstract 3972: MicroRNAs as potential therapeutic agents for AML: Targeting the AML1-ETO Oncogene by pre-miR-520 and -373 (2015) (0)
acute myeloid leukemia cells Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of (2011) (0)
Inhibition of the deubiquitinase USP10 induces degradation of SYK (2020) (0)
The application of monoclonal antibodies for the detection and classification of AML (1986) (0)
NADPH Oxidases Are Important Regulators of Growth and Migration in Myeloid Neoplasms. (2009) (0)
Adverse events associated with escalating imatinib versus switching to dasatinib in patients with chronic myelegenous leukemia. (2016) (0)
monocytes Independent regulation of M-CSF and G-CSF gene expression in human (2011) (0)
Molecular Cancer apeutics apeutic Discovery overy and Characterization of Novel Mutant Ther 3 Kinase Inhibitors (2010) (0)
Selected Abstracts presented at the 8th Annual Meeting of the Hematology/Oncology Pharmacy Association, 21–24 March 2012, Orlando, Florida, USA (2012) (0)
Gaining an advantage: mycophenolate-resistance for adoptively transferred cells (2012) (0)
Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase of a Potent and Selective DDR1 Receptor Tyrosine Kinase (2013) (0)
hematologic malignancies After chronic myelogenous leukemia: tyrosine kinase inhibitors in other (2013) (0)
Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia (2015) (0)
PKC 412 FLT3 inhibitor therapy in AML (2004) (0)
Identification of Wee1 and IGF-1R As Novel Therapeutic Targets for Mutant RAS-Driven Acute Leukemia By Combinatory Chemical Screens (2014) (0)
leukemia or chronic lymphocytic leukemia leukemia and acute myeloid leukemia, but not in acute lymphoblastic The JAK2V617F activating mutation occurs in chronic myelomonocytic (2013) (0)
Interview With U.S. Surgeon General Jerome Adams, M.D. (2018) (0)
Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells (2013) (0)
FOXO3a Regulates Survival and Proliferative Signaling Through Modulation of The NPM-ALK Fusion Kinase of Anaplastic Large Cell Lymphoma (2013) (0)
A Two-Color Flow Cytometry Assay for Detection of Hairy Cells Using Monoclonal Antibodies (2005) (0)
and CML Progenitors Functionally Normal and Nontumorigenic In Vivo Vector That Renders Hematopoietic Progenitors Methotrexate-Resistant Gene Therapy for Chronic Myelogenous Leukemia (CML): A Retroviral (2010) (0)
EPO906 (Epothilone B) inhibits cell growth and survival of multiple myeloma cells in the bone marrow microenvironment, in vitro and in vivo. (2002) (0)
Pim Kinases Mediate Viability Signals Downstream of the Tyrosine Kinase Oncogenes BCR-ABL and FLT3-ITD. (2004) (0)
In Vitro Anti-Myeloma Activity of the Multitargeted Kinase Inhibitor Midostaurin in the Context of Heterotypic Cocultures of Myeloma Cells with Nonmalignant Microenvironmental Accessory Cells (2011) (0)
Activation of Notch1 Signaling Suppresses Granulocytic Differentiation and Maintains a Part of Myeloid Progenitor Cells At the Immature Stage (2011) (0)
phosphorylation in human myeloid cells factor receptor is not required for induction of protein tyrosine Internalization of the granulocyte-macrophage colony-stimulating (2011) (0)
Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery. (2009) (0)
A monoclonal antibody specific to the functional adhesion area of the surface protein of a phagocyte cell. (1988) (0)
A novel risk of air embolism with intravenous paracetamol (2012) (0)
Genome-Wide Aberrant Splicing in Patients with Acute Myelold Leukemia (AML) Is Associated with Altered Expression of Splicing Factors (2012) (0)
~ 2 1 0 ~ " ~ ' ~ ~ ' and p160v-Ab1 Induce an Increase in the Tyrosine Phosphorylation of p93"-Fes* (2001) (0)

This paper list is powered by the following services:

Other Resources About James D. Griffin

en.wikipedia.org

What Schools Are Affiliated With James D. Griffin ?

James D. Griffin is affiliated with the following schools: